Assessment of Needs
Medical cannabis is now legal in the majority of US states. Most individuals seeking medical cannabis do so for pain, which is common in people with HIV (PWH), and there has been increasing interest in understanding the role of cannabis in reducing opioid prescribing and treating opioid use disorder. This talk will review the state of the science of medical cannabis for pain and opioid use and use disorder in PWH, and will provide evidence-based talking points for conversations with patients and colleagues.
This webinar is part 2 of the 4-part webinar series on pain and addiction:
- Part 1: Chronic Pain in People With HIV: An Evidence-Based, Practical Approach by Dr Jessica Merlin, MD, PhD, MBA (University of Pittsburgh)
- Part 3: Opioid Use and HIV/Hepatitis C Made Easy: A Practical Implementation of the Evidence by Dr R. Douglas Bruce, MD, MA, MS (Yale School of Medicine)
- Part 4: More Than One Problem: Mental Illness as a Contributing Factor of Pain and Substance Use in People With HIV by Dr R. Douglas Bruce, MD, MA, MS (Yale School of Medicine)
Upon completion of this webinar, learners will be able to:
- Explain the evidence base for using medical cannabis in people with HIV
- Describe to patients and colleagues the benefits and risks of medical cannabis in people with HIV
Note: The IAS–USA acknowledges the importance of delivering the same high-quality education and resources to our audiences despite the challenging times we are experiencing due to the COVID-19 pandemic. In response, the implementation of a nominal fee to process the claim of CME and CE credits for webinars has been postponed.
Who Should Attend
This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday, October 5, 2020, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at firstname.lastname@example.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Dr Merlin has no relevant financial affiliations to disclose. (Updated 08/28/20)
Planner/Reviewer 1 has no relevant financial affiliations to disclose. (Updated 09/30/20)
Planner/Reviewer 2 has no relevant financial affiliations to disclose. (Updated 09/30/20)
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
This program is approved for 1.25 hours of pharmacotherapy credit.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-20-267-L02-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Merck & Co, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.